How to Manage Nausea, Vomiting, and Other GI Side Effects on GLP-1 Drugs: Expert Consensus Guidelines | Research

The takeaway

A multidisciplinary expert panel developed practical recommendations for managing the nausea, vomiting, diarrhea, and constipation that commonly occur with GLP-1 drugs.

12 experts, 6 specialties
Endocrinologists, nephrologists, cardiologists, primary care physicians, internists, and diabetes educators collaborated on these GI management guidelines

What the researchers found

A multidisciplinary panel of 12 experts (endocrinologists, nephrologists, cardiologists, primary care physicians, internists, and diabetes educators) developed consensus recommendations for managing the gastrointestinal side effects of GLP-1 drugs. The guidelines cover how to properly escalate doses to reduce GI symptoms, what to do when nausea, vomiting, diarrhea, or constipation develop during treatment, and practical clinical scenarios that doctors encounter regularly. The goal is to keep patients on therapy rather than having them quit due to side effects.

Why it matters

GI side effects are the number one reason people stop taking GLP-1 drugs — and stopping means losing the blood sugar and weight loss benefits. Yet many patients quit simply because they or their doctors don't know how to manage the symptoms. This consensus provides the first structured, multi-specialty guidance specifically focused on GLP-1 GI side effect management, filling a gap that has real consequences for millions of patients.

How the study worked

An expert panel of 12 specialists across six medical disciplines (endocrinology, nephrology, primary care, cardiology, internal medicine, and diabetes nursing) met virtually to review evidence and clinical experience. They developed consensus recommendations through structured discussion, created clinical scenarios representing common situations, and designed infographics for both clinicians and patients.

Who was studied

Expert consensus — recommendations apply to patients with type 2 diabetes and/or obesity on GLP-1 receptor agonist therapy

What this study cannot tell us

This is an expert consensus document, not a systematic review or clinical trial. Recommendations are based on the panel's clinical experience and interpretation of existing evidence, which may not always be backed by randomized trial data. The consensus was developed by Spanish experts and some recommendations may reflect regional practice patterns.

How to read the evidence

This is an expert consensus document — the lowest tier of the evidence hierarchy, but valuable for translating existing knowledge into practical clinical guidance. The recommendations reflect collective clinical experience rather than new trial data.

When this study was published

Published in late 2022, these guidelines were developed as GLP-1 prescribing was rapidly expanding. While the core principles remain applicable, newer drugs (tirzepatide, oral semaglutide at higher doses) may require updated recommendations.

The bigger picture

As GLP-1 drugs have become some of the most prescribed medications worldwide, the practical challenge of managing their side effects has become a major clinical issue. Many prescribers — especially in primary care — lack specific training in GLP-1 GI management. This consensus fills that gap with actionable, specialty-spanning guidance. The key insight is that most GI side effects are manageable and temporary (especially during dose escalation), but without proper guidance, patients often discontinue prematurely and lose significant health benefits.

Questions still open

Do patients who follow structured GI management protocols have lower discontinuation rates than those who don't?
Are these recommendations equally applicable to newer GLP-1 drugs like tirzepatide and oral semaglutide?
Would patient-facing educational materials based on these guidelines improve adherence in real-world settings?

Common questions

Why do GLP-1 drugs cause nausea and stomach problems?

GLP-1 drugs slow down how fast your stomach empties food into the intestines — this is actually part of how they help with weight loss and blood sugar control. But this slower emptying can cause nausea, bloating, and other GI symptoms, especially when you first start the medication or increase the dose. Most people's bodies adjust over time.

What's the most important tip for avoiding GI side effects on GLP-1 drugs?

Gradual dose escalation is key — starting at a low dose and increasing slowly gives your body time to adjust. The expert panel also recommends eating smaller meals, avoiding fatty or spicy foods, and staying hydrated. If symptoms are severe, the dose increase can be paused or even temporarily reduced until they settle.

Read the original research

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.

Journal of clinical medicine, 12(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Gorgojo-Martínez, Juan J; Mezquita-Raya, Pedro; Carretero-Gómez, Juana; Castro, Almudena; Cebrián-Cuenca, Ana; de Torres-Sánchez, Alejandra; García-de-Lucas, María Dolores; Núñez, Julio; Obaya, Juan Carlos; Soler, María José; Górriz, José Luis; Rubio-Herrera, Miguel Ángel. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.. Journal of clinical medicine, 12(1). https://doi.org/10.3390/jcm12010145